What changed
$SYK — Designs and manufactures medical devices for surgery.
🎯 Q1 FY26 | Rev $6B | EPS $2.60 vs $2.98 🔴 | Margin 25.7%
💡 Consensus expected Q1 2026 EPS of $2.98, but Stryker reported $2.60 (a 12.86% miss). The market likely overestimated the pace of recovery in elective procedures and margin expansion. However, Stryker reaffirmed full-year 2026 guidance of $14.90-$15.10 adjusted EPS, implying a strong back-half ramp.
🏢 Business Quality: 8/10 | Valuation: fair
📉 Reward/Risk: Upside 10% to $334 (consensus PT) vs downside 15% to $258 (if guidance is cut). Ratio ~0.67:1, unfavorable for a short-term trade.
🔮 Catalyst: Q2 2026 earnings (late July 2026): Need to see sequential improvement in organic growth and margins. Key metric: organic sales growth and adjusted EPS vs. consensus of $3.68. Failure signal: if Q2 guidance is lowered or organic growth <6%.
Also in play: $WCN $RSG $WM $ECL $CLH $CNHI